Implementing treat-to-target urate-lowering therapy during hospitalizations for gout flares

被引:0
|
作者
Russell, Mark D. [1 ,8 ]
Ameyaw-Kyeremeh, Louise [2 ]
Dell'Accio, Flora [1 ]
Lapham, Heather [2 ]
Head, Natalie [2 ]
Stovin, Christopher [2 ]
Patel, Vishit [2 ]
Clarke, Benjamin D. [2 ]
Nagra, Deepak [1 ]
Alveyn, Edward [1 ]
Adas, Maryam A. [1 ]
Bechman, Katie [1 ]
de la Puente, Maria A. [3 ]
Ellis, Benjamin [4 ]
Byrne, Corrine [5 ]
Patel, Rina
Rutherford, Andrew, I [2 ]
Cantle, Fleur [6 ]
Norton, Sam [1 ]
Roddy, Edward [7 ]
Hudson, Joanna [3 ]
Cope, Andrew P. [1 ]
Galloway, James B. [1 ]
机构
[1] Kings Coll London, Ctr Rheumat Dis, London, England
[2] Kings Coll Hosp NHS Fdn Trust, Dept Rheumatol, London, England
[3] Kings Coll London, Inst Psychiat Psychol & Neurosci, Dept Psychol, Hlth Psychol Sect, London, England
[4] Imperial Coll Healthcare NHS Fdn Trust, Dept Rheumatol, London, England
[5] Kings Coll Hosp NHS Fdn Trust, Pharm Dept, London, England
[6] Kings Coll Hosp NHS Fdn Trust, Dept Emergency Med, London, England
[7] Keele Univ, Sch Med, Keele, England
[8] Kings Coll London, Ctr Rheumat Dis, Weston Educ Ctr, 10 Cutcombe Rd, London SE5 9RJ, England
基金
美国国家卫生研究院;
关键词
gout; crystal arthritis; hospital; admissions; urate-lowering therapy; allopurinol; RHEUMATOID-ARTHRITIS HOSPITALIZATIONS; MANAGEMENT; ALLOPURINOL; INITIATION; PROLONG; TRENDS; UK;
D O I
10.1093/rheumatology/kead574
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives: To evaluate a strategy designed to optimize care and increase uptake of urate-lowering therapy (ULT) during hospitalizations for gout flares.Methods: We conducted a prospective cohort study to evaluate a strategy that combined optimal in-hospital gout management with a nurse-led, follow-up appointment, followed by handover to primary care. Outcomes, including ULT initiation, urate target attainment and re-hospitalization rates, were compared between patients hospitalized for flares in the 12 months post-implementation and a retrospective cohort of hospitalized patients from 12 months pre-implementation.Results: One hundred and nineteen and 108 patients, respectively, were hospitalized for gout flares in the 12 months pre- and post-implementation. For patients with 6-month follow-up data available (n = 94 and n = 97, respectively), the proportion newly initiated on ULT increased from 49.2% pre-implementation to 92.3% post-implementation (age/sex-adjusted odds ratio [aOR] 11.5; 95% CI 4.36, 30.5; P < 0.001). After implementation, more patients achieved a serum urate <= 360 mu mol/l within 6 months of discharge (10.6% pre-implementation vs 26.8% post-implementation; aOR 3.04; 95% CI 1.36, 6.78; P = 0.007). The proportion of patients re-hospitalized for flares was 14.9% pre-implementation vs 9.3% post-implementation (aOR 0.53; 95% CI 0.22, 1.32; P = 0.18).Conclusion: Over 90% of patients were initiated on ULT after implementing a strategy to optimize hospital gout care. Despite increased initiation of ULT during flares, recurrent hospitalizations were not more frequent following implementation. Significant relative improvements in urate target attainment were observed post-implementation; however, for the majority of hospitalized gout patients to achieve urate targets, closer primary-secondary care integration is still needed.
引用
收藏
页码:2222 / 2229
页数:8
相关论文
共 50 条
  • [21] Urate-Lowering Therapy for Gout: Focus on Febuxostat
    Love, Bryan L.
    Barrons, Robert
    Veverka, Angie
    Snider, K. Matthew
    PHARMACOTHERAPY, 2010, 30 (06): : 594 - 608
  • [22] RILONACEPT REDUCES THE OCCURRENCE OF GOUT FLARES THAT MAY BE PRECIPITATED BY INITIATION OF URATE-LOWERING THERAPY
    Knapp, H. R.
    Schumacher, R.
    Sundy, J. S.
    Terkeltauab, R.
    Mellis, S.
    King-Davis, S.
    Wu, R.
    Weinstein, S.
    Radin, A.
    JOURNAL OF GENERAL INTERNAL MEDICINE, 2009, 24 : 164 - 164
  • [23] Gout Flares After Stopping Anti-inflammatory Prophylaxis During the Early Phases of Urate-Lowering Therapy
    Stamp, Lisa
    Frampton, Chris
    O'Dell, James
    Mikuls, Ted
    Newcomb, Jeff
    Dalbeth, Nicola
    ARTHRITIS & RHEUMATOLOGY, 2024, 76 : 4079 - 4080
  • [24] The Influence of Treat-to-target Urate Lowering Therapy and Anti-inflammatory Prophylaxis on Circulating Measures of Inflammation in Gout
    Wheeler, Austin
    Ourada, Tanner
    Duryee, Michael
    England, Bryant
    Reynolds, Richard
    O'Dell, James
    Newcomb, Jeff
    Pillinger, Michael
    Terkeltaub, Robert
    Ferguson, Ryan
    Brophy, Mary
    Merriman, Tony
    Mikuls, Ted
    ARTHRITIS & RHEUMATOLOGY, 2024, 76 : 4085 - 4086
  • [25] What Is the Evidence for Treat-to-Target Serum Urate in Gout?
    David Bursill
    Nicola Dalbeth
    Current Rheumatology Reports, 2018, 20
  • [26] When underlying biology threatens the randomization principle — initial gout flares of urate-lowering therapy
    Hyon K. Choi
    Yuqing Zhang
    Nicola Dalbeth
    Nature Reviews Rheumatology, 2022, 18 : 543 - 549
  • [27] When underlying biology threatens the randomization principle - initial gout flares of urate-lowering therapy
    Choi, Hyon K.
    Zhang, Yuqing
    Dalbeth, Nicola
    NATURE REVIEWS RHEUMATOLOGY, 2022, 18 (09) : 543 - 549
  • [28] What Is the Evidence for Treat-to-Target Serum Urate in Gout?
    Bursill, David
    Dalbeth, Nicola
    CURRENT RHEUMATOLOGY REPORTS, 2018, 20 (03)
  • [29] The Effect of Decrease in Serum Urate for the Risk of Gout Flares During Urate-Lowering Therapy Initiation Among Chinese Male Gout Patients: A Prospective Cohort Study
    Pang, Lei
    Xue, Xiaomei
    He, Yuwei
    Wang, Can
    Han, Lin
    Li, Maichao
    Qi, Han
    Li, Changgui
    Lu, Jie
    JOURNAL OF INFLAMMATION RESEARCH, 2023, 16 : 3937 - 3947
  • [30] Prediction of renal and cardiometabolic outcomes in gout during urate-lowering therapy by sonography
    Calabuig, Irene
    Marty-Ane, Anne
    Norberciak, Laurene
    Budzik, Jean-Francois
    Legrand, Julie
    Martinez-Sanchis, Agustin
    Pascart, Tristan
    Andres, Mariano
    INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES, 2023, 26 (12) : 2450 - 2459